Table of Content

1 Report Overview
1.1 Trastuzumab Biosimilar Definition
1.2 Market by Type
1.2.1 Global Trastuzumab Biosimilar Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Adjuvant Breast Cancer
1.2.3 Metastatic Breast Cancer
1.2.4 Metastatic Gastric Cancer
1.2.5 Others
1.3 Market Segment by Application
1.3.1 Global Trastuzumab Biosimilar Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital Pharmacy
1.3.3 Online Pharmacy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Trastuzumab Biosimilar Sales
2.1 Global Trastuzumab Biosimilar Revenue Estimates and Forecasts 2018-2034
2.2 Global Trastuzumab Biosimilar Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Trastuzumab Biosimilar Revenue by Region
2.3.1 Global Trastuzumab Biosimilar Revenue by Region (2018-2024)
2.3.2 Global Trastuzumab Biosimilar Revenue by Region (2024-2034)
2.4 Global Trastuzumab Biosimilar Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Trastuzumab Biosimilar Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Trastuzumab Biosimilar Sales Quantity by Region
2.6.1 Global Trastuzumab Biosimilar Sales Quantity by Region (2018-2024)
2.6.2 Global Trastuzumab Biosimilar Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Trastuzumab Biosimilar Sales Quantity by Manufacturers
3.1.1 Global Trastuzumab Biosimilar Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Trastuzumab Biosimilar Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Trastuzumab Biosimilar Sales in 2022
3.2 Global Trastuzumab Biosimilar Revenue by Manufacturers
3.2.1 Global Trastuzumab Biosimilar Revenue by Manufacturers (2018-2024)
3.2.2 Global Trastuzumab Biosimilar Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Trastuzumab Biosimilar Revenue in 2022
3.3 Global Trastuzumab Biosimilar Sales Price by Manufacturers
3.4 Global Key Players of Trastuzumab Biosimilar, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Trastuzumab Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Trastuzumab Biosimilar, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Trastuzumab Biosimilar, Product Offered and Application
3.8 Global Key Manufacturers of Trastuzumab Biosimilar, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Trastuzumab Biosimilar Sales Quantity by Type
4.1.1 Global Trastuzumab Biosimilar Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Trastuzumab Biosimilar Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Trastuzumab Biosimilar Sales Quantity Market Share by Type (2018-2034)
4.2 Global Trastuzumab Biosimilar Revenue by Type
4.2.1 Global Trastuzumab Biosimilar Historical Revenue by Type (2018-2024)
4.2.2 Global Trastuzumab Biosimilar Forecasted Revenue by Type (2024-2034)
4.2.3 Global Trastuzumab Biosimilar Revenue Market Share by Type (2018-2034)
4.3 Global Trastuzumab Biosimilar Price by Type
4.3.1 Global Trastuzumab Biosimilar Price by Type (2018-2024)
4.3.2 Global Trastuzumab Biosimilar Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Trastuzumab Biosimilar Sales Quantity by Application
5.1.1 Global Trastuzumab Biosimilar Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Trastuzumab Biosimilar Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Trastuzumab Biosimilar Sales Quantity Market Share by Application (2018-2034)
5.2 Global Trastuzumab Biosimilar Revenue by Application
5.2.1 Global Trastuzumab Biosimilar Historical Revenue by Application (2018-2024)
5.2.2 Global Trastuzumab Biosimilar Forecasted Revenue by Application (2024-2034)
5.2.3 Global Trastuzumab Biosimilar Revenue Market Share by Application (2018-2034)
5.3 Global Trastuzumab Biosimilar Price by Application
5.3.1 Global Trastuzumab Biosimilar Price by Application (2018-2024)
5.3.2 Global Trastuzumab Biosimilar Price Forecast by Application (2024-2034)
6 North America
6.1 North America Trastuzumab Biosimilar Sales by Company
6.1.1 North America Trastuzumab Biosimilar Revenue by Company (2018-2024)
6.1.2 North America Trastuzumab Biosimilar Sales Quantity by Company (2018-2024)
6.2 North America Trastuzumab Biosimilar Market Size by Type
6.2.1 North America Trastuzumab Biosimilar Sales Quantity by Type (2018-2034)
6.2.2 North America Trastuzumab Biosimilar Revenue by Type (2018-2034)
6.3 North America Trastuzumab Biosimilar Market Size by Application
6.3.1 North America Trastuzumab Biosimilar Sales Quantity by Application (2018-2034)
6.3.2 North America Trastuzumab Biosimilar Revenue by Application (2018-2034)
6.4 North America Trastuzumab Biosimilar Market Size by Country
6.4.1 North America Trastuzumab Biosimilar Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Trastuzumab Biosimilar Revenue by Country (2018-2034)
6.4.3 North America Trastuzumab Biosimilar Sales Quantity by Country (2018-2034)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Trastuzumab Biosimilar Sales by Company
7.1.1 Europe Trastuzumab Biosimilar Sales Quantity by Company (2018-2024)
7.1.2 Europe Trastuzumab Biosimilar Revenue by Company (2018-2024)
7.2 Europe Trastuzumab Biosimilar Market Size by Type
7.2.1 Europe Trastuzumab Biosimilar Sales Quantity by Type (2018-2034)
7.2.2 Europe Trastuzumab Biosimilar Revenue by Type (2018-2034)
7.3 Europe Trastuzumab Biosimilar Market Size by Application
7.3.1 Europe Trastuzumab Biosimilar Sales Quantity by Application (2018-2034)
7.3.2 Europe Trastuzumab Biosimilar Revenue by Application (2018-2034)
7.4 Europe Trastuzumab Biosimilar Market Size by Country
7.4.1 Europe Trastuzumab Biosimilar Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Trastuzumab Biosimilar Revenue by Country (2018-2034)
7.4.3 Europe Trastuzumab Biosimilar Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Trastuzumab Biosimilar Sales by Company
8.1.1 China Trastuzumab Biosimilar Sales Quantity by Company (2018-2024)
8.1.2 China Trastuzumab Biosimilar Revenue by Company (2018-2024)
8.2 China Trastuzumab Biosimilar Market Size by Type
8.2.1 China Trastuzumab Biosimilar Sales Quantity by Type (2018-2034)
8.2.2 China Trastuzumab Biosimilar Revenue by Type (2018-2034)
8.3 China Trastuzumab Biosimilar Market Size by Application
8.3.1 China Trastuzumab Biosimilar Sales Quantity by Application (2018-2034)
8.3.2 China Trastuzumab Biosimilar Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Trastuzumab Biosimilar Sales by Company
9.1.1 APAC Trastuzumab Biosimilar Sales Quantity by Company (2018-2024)
9.1.2 APAC Trastuzumab Biosimilar Revenue by Company (2018-2024)
9.2 APAC Trastuzumab Biosimilar Market Size by Type
9.2.1 APAC Trastuzumab Biosimilar Sales Quantity by Type (2018-2034)
9.2.2 APAC Trastuzumab Biosimilar Revenue by Type (2018-2034)
9.3 APAC Trastuzumab Biosimilar Market Size by Application
9.3.1 APAC Trastuzumab Biosimilar Sales Quantity by Application (2018-2034)
9.3.2 APAC Trastuzumab Biosimilar Revenue by Application (2018-2034)
9.4 APAC Trastuzumab Biosimilar Market Size by Region
9.4.1 APAC Trastuzumab Biosimilar Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Trastuzumab Biosimilar Revenue by Region (2018-2034)
9.4.3 APAC Trastuzumab Biosimilar Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Trastuzumab Biosimilar Sales by Company
10.1.1 Middle East, Africa and Latin America Trastuzumab Biosimilar Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Trastuzumab Biosimilar Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Trastuzumab Biosimilar Market Size by Type
10.2.1 Middle East, Africa and Latin America Trastuzumab Biosimilar Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Trastuzumab Biosimilar Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Trastuzumab Biosimilar Market Size by Application
10.3.1 Middle East, Africa and Latin America Trastuzumab Biosimilar Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Trastuzumab Biosimilar Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Trastuzumab Biosimilar Market Size by Country
10.4.1 Middle East, Africa and Latin America Trastuzumab Biosimilar Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Trastuzumab Biosimilar Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Trastuzumab Biosimilar Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Amgen Inc.
11.1.1 Amgen Inc. Company Information
11.1.2 Amgen Inc. Overview
11.1.3 Amgen Inc. Trastuzumab Biosimilar Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Amgen Inc. Trastuzumab Biosimilar Products and Services
11.1.5 Amgen Inc. Trastuzumab Biosimilar SWOT Analysis
11.1.6 Amgen Inc. Recent Developments
11.2 Pfizer Inc
11.2.1 Pfizer Inc Company Information
11.2.2 Pfizer Inc Overview
11.2.3 Pfizer Inc Trastuzumab Biosimilar Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Pfizer Inc Trastuzumab Biosimilar Products and Services
11.2.5 Pfizer Inc Trastuzumab Biosimilar SWOT Analysis
11.2.6 Pfizer Inc Recent Developments
11.3 Samsung Bioepis
11.3.1 Samsung Bioepis Company Information
11.3.2 Samsung Bioepis Overview
11.3.3 Samsung Bioepis Trastuzumab Biosimilar Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Samsung Bioepis Trastuzumab Biosimilar Products and Services
11.3.5 Samsung Bioepis Trastuzumab Biosimilar SWOT Analysis
11.3.6 Samsung Bioepis Recent Developments
11.4 Merck & Co.
11.4.1 Merck & Co. Company Information
11.4.2 Merck & Co. Overview
11.4.3 Merck & Co. Trastuzumab Biosimilar Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Merck & Co. Trastuzumab Biosimilar Products and Services
11.4.5 Merck & Co. Trastuzumab Biosimilar SWOT Analysis
11.4.6 Merck & Co. Recent Developments
11.5 Biocon Limited
11.5.1 Biocon Limited Company Information
11.5.2 Biocon Limited Overview
11.5.3 Biocon Limited Trastuzumab Biosimilar Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Biocon Limited Trastuzumab Biosimilar Products and Services
11.5.5 Biocon Limited Trastuzumab Biosimilar SWOT Analysis
11.5.6 Biocon Limited Recent Developments
11.6 Teva Pharmaceutical
11.6.1 Teva Pharmaceutical Company Information
11.6.2 Teva Pharmaceutical Overview
11.6.3 Teva Pharmaceutical Trastuzumab Biosimilar Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Teva Pharmaceutical Trastuzumab Biosimilar Products and Services
11.6.5 Teva Pharmaceutical Trastuzumab Biosimilar SWOT Analysis
11.6.6 Teva Pharmaceutical Recent Developments
11.7 Genentech
11.7.1 Genentech Company Information
11.7.2 Genentech Overview
11.7.3 Genentech Trastuzumab Biosimilar Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Genentech Trastuzumab Biosimilar Products and Services
11.7.5 Genentech Trastuzumab Biosimilar SWOT Analysis
11.7.6 Genentech Recent Developments
11.8 Mundipharma
11.8.1 Mundipharma Company Information
11.8.2 Mundipharma Overview
11.8.3 Mundipharma Trastuzumab Biosimilar Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 Mundipharma Trastuzumab Biosimilar Products and Services
11.8.5 Mundipharma Trastuzumab Biosimilar SWOT Analysis
11.8.6 Mundipharma Recent Developments
11.9 Celltrion
11.9.1 Celltrion Company Information
11.9.2 Celltrion Overview
11.9.3 Celltrion Trastuzumab Biosimilar Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.9.4 Celltrion Trastuzumab Biosimilar Products and Services
11.9.5 Celltrion Trastuzumab Biosimilar SWOT Analysis
11.9.6 Celltrion Recent Developments
11.10 Henlius
11.10.1 Henlius Company Information
11.10.2 Henlius Overview
11.10.3 Henlius Trastuzumab Biosimilar Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.10.4 Henlius Trastuzumab Biosimilar Products and Services
11.10.5 Henlius Trastuzumab Biosimilar SWOT Analysis
11.10.6 Henlius Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Trastuzumab Biosimilar Value Chain Analysis
12.2 Trastuzumab Biosimilar Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Trastuzumab Biosimilar Production Mode & Process
12.4 Trastuzumab Biosimilar Sales and Marketing
12.4.1 Trastuzumab Biosimilar Sales Channels
12.4.2 Trastuzumab Biosimilar Distributors
12.5 Trastuzumab Biosimilar Customers
13 Market Dynamics
13.1 Trastuzumab Biosimilar Industry Trends
13.2 Trastuzumab Biosimilar Market Drivers
13.3 Trastuzumab Biosimilar Market Challenges
13.4 Trastuzumab Biosimilar Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Trastuzumab Biosimilar Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Adjuvant Breast Cancer
Table 3. Major Manufacturers of Metastatic Breast Cancer
Table 4. Major Manufacturers of Metastatic Gastric Cancer
Table 5. Major Manufacturers of Others
Table 6. Global Trastuzumab Biosimilar Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Trastuzumab Biosimilar Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Trastuzumab Biosimilar Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Trastuzumab Biosimilar Revenue Market Share by Region (2018-2024)
Table 10. Global Trastuzumab Biosimilar Revenue by Region (2024-2034) & (US$ Million)
Table 11. Global Trastuzumab Biosimilar Revenue Market Share by Region (2024-2034)
Table 12. Global Trastuzumab Biosimilar Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Units)
Table 13. Global Trastuzumab Biosimilar Sales by Region (2018-2024) & (K Units)
Table 14. Global Trastuzumab Biosimilar Sales Market Share by Region (2018-2024)
Table 15. Global Trastuzumab Biosimilar Sales by Region (2024-2034) & (K Units)
Table 16. Global Trastuzumab Biosimilar Sales Market Share by Region (2024-2034)
Table 17. Global Trastuzumab Biosimilar Sales Quantity by Manufacturers (2018-2024) & (K Units)
Table 18. Global Trastuzumab Biosimilar Sales Quantity Share by Manufacturers (2018-2024)
Table 19. Global Trastuzumab Biosimilar Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Trastuzumab Biosimilar Revenue Share by Manufacturers (2018-2024)
Table 21. Global Trastuzumab Biosimilar Price by Manufacturers 2018-2024 (US$/Unit)
Table 22. Global Key Players of Trastuzumab Biosimilar, Industry Ranking, 2021 VS 2022
Table 23. Global Trastuzumab Biosimilar Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Trastuzumab Biosimilar by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Trastuzumab Biosimilar as of 2022)
Table 25. Global Key Manufacturers of Trastuzumab Biosimilar, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Trastuzumab Biosimilar, Product Offered and Application
Table 27. Global Key Manufacturers of Trastuzumab Biosimilar, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Trastuzumab Biosimilar Sales Quantity by Type (2018-2024) & (K Units)
Table 30. Global Trastuzumab Biosimilar Sales Quantity by Type (2024-2034) & (K Units)
Table 31. Global Trastuzumab Biosimilar Sales Quantity Share by Type (2018-2024)
Table 32. Global Trastuzumab Biosimilar Sales Quantity Share by Type (2024-2034)
Table 33. Global Trastuzumab Biosimilar Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Trastuzumab Biosimilar Revenue by Type (2024-2034) & (US$ Million)
Table 35. Global Trastuzumab Biosimilar Revenue Share by Type (2018-2024)
Table 36. Global Trastuzumab Biosimilar Revenue Share by Type (2024-2034)
Table 37. Trastuzumab Biosimilar Price by Type (2018-2024) & (US$/Unit)
Table 38. Global Trastuzumab Biosimilar Price Forecast by Type (2024-2034) & (US$/Unit)
Table 39. Global Trastuzumab Biosimilar Sales Quantity by Application (2018-2024) & (K Units)
Table 40. Global Trastuzumab Biosimilar Sales Quantity by Application (2024-2034) & (K Units)
Table 41. Global Trastuzumab Biosimilar Sales Quantity Share by Application (2018-2024)
Table 42. Global Trastuzumab Biosimilar Sales Quantity Share by Application (2024-2034)
Table 43. Global Trastuzumab Biosimilar Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Trastuzumab Biosimilar Revenue by Application (2024-2034) & (US$ Million)
Table 45. Global Trastuzumab Biosimilar Revenue Share by Application (2018-2024)
Table 46. Global Trastuzumab Biosimilar Revenue Share by Application (2024-2034)
Table 47. Trastuzumab Biosimilar Price by Application (2018-2024) & (US$/Unit)
Table 48. Global Trastuzumab Biosimilar Price Forecast by Application (2024-2034) & (US$/Unit)
Table 49. North America Trastuzumab Biosimilar Revenue by Company (2018-2024) & (US$ Million)
Table 50. North America Trastuzumab Biosimilar Sales Quantity by Company (2018-2024) & (K Units)
Table 51. North America Trastuzumab Biosimilar Sales Quantity by Type (2018-2024) & (K Units)
Table 52. North America Trastuzumab Biosimilar Sales Quantity by Type (2024-2034) & (K Units)
Table 53. North America Trastuzumab Biosimilar Revenue by Type (2018-2024) & (US$ Million)
Table 54. North America Trastuzumab Biosimilar Revenue by Type (2024-2034) & (US$ Million)
Table 55. North America Trastuzumab Biosimilar Sales Quantity by Application (2018-2024) & (K Units)
Table 56. North America Trastuzumab Biosimilar Sales Quantity by Application (2024-2034) & (K Units)
Table 57. North America Trastuzumab Biosimilar Revenue by Application (2018-2024) & (US$ Million)
Table 58. North America Trastuzumab Biosimilar Revenue by Application (2024-2034) & (US$ Million)
Table 59. North America Trastuzumab Biosimilar Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 60. North America Trastuzumab Biosimilar Revenue by Country (2018-2024) & (US$ Million)
Table 61. North America Trastuzumab Biosimilar Revenue by Country (2024-2034) & (US$ Million)
Table 62. North America Trastuzumab Biosimilar Sales Quantity by Country (2018-2024) & (K Units)
Table 63. North America Trastuzumab Biosimilar Sales Quantity by Country (2024-2034) & (K Units)
Table 64. Europe Trastuzumab Biosimilar Sales Quantity by Company (2018-2024) & (K Units)
Table 65. Europe Trastuzumab Biosimilar Revenue by Company (2018-2024) & (US$ Million)
Table 66. Europe Trastuzumab Biosimilar Sales Quantity by Type (2018-2024) & (K Units)
Table 67. Europe Trastuzumab Biosimilar Sales Quantity by Type (2024-2034) & (K Units)
Table 68. Europe Trastuzumab Biosimilar Revenue by Type (2018-2024) & (US$ Million)
Table 69. Europe Trastuzumab Biosimilar Revenue by Type (2024-2034) & (US$ Million)
Table 70. Europe Trastuzumab Biosimilar Sales Quantity by Application (2018-2024) & (K Units)
Table 71. Europe Trastuzumab Biosimilar Sales Quantity by Application (2024-2034) & (K Units)
Table 72. Europe Trastuzumab Biosimilar Revenue by Application (2018-2024) & (US$ Million)
Table 73. Europe Trastuzumab Biosimilar Revenue by Application (2024-2034) & (US$ Million)
Table 74. Europe Trastuzumab Biosimilar Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 75. Europe Trastuzumab Biosimilar Revenue by Country (2018-2024) & (US$ Million)
Table 76. Europe Trastuzumab Biosimilar Revenue by Country (2024-2034) & (US$ Million)
Table 77. Europe Trastuzumab Biosimilar Sales Quantity by Country (2018-2024) & (K Units)
Table 78. Europe Trastuzumab Biosimilar Sales Quantity by Country (2024-2034) & (K Units)
Table 79. China Trastuzumab Biosimilar Sales Quantity by Company (2018-2024) & (K Units)
Table 80. China Trastuzumab Biosimilar Revenue by Company (2018-2024) & (US$ Million)
Table 81. China Trastuzumab Biosimilar Sales Quantity by Type (2018-2024) & (K Units)
Table 82. China Trastuzumab Biosimilar Sales Quantity by Type (2024-2034) & (K Units)
Table 83. China Trastuzumab Biosimilar Revenue by Type (2018-2024) & (US$ Million)
Table 84. China Trastuzumab Biosimilar Revenue by Type (2024-2034) & (US$ Million)
Table 85. China Trastuzumab Biosimilar Sales Quantity by Application (2018-2024) & (K Units)
Table 86. China Trastuzumab Biosimilar Sales Quantity by Application (2024-2034) & (K Units)
Table 87. China Trastuzumab Biosimilar Revenue by Application (2018-2024) & (US$ Million)
Table 88. China Trastuzumab Biosimilar Revenue by Application (2024-2034) & (US$ Million)
Table 89. APAC Trastuzumab Biosimilar Sales Quantity by Company (2018-2024) & (K Units)
Table 90. APAC Trastuzumab Biosimilar Revenue by Company (2018-2024) & (US$ Million)
Table 91. APAC Trastuzumab Biosimilar Sales Quantity by Type (2018-2024) & (K Units)
Table 92. APAC Trastuzumab Biosimilar Sales Quantity by Type (2024-2034) & (K Units)
Table 93. APAC Trastuzumab Biosimilar Revenue by Type (2018-2024) & (US$ Million)
Table 94. APAC Trastuzumab Biosimilar Revenue by Type (2024-2034) & (US$ Million)
Table 95. APAC Trastuzumab Biosimilar Sales Quantity by Application (2018-2024) & (K Units)
Table 96. APAC Trastuzumab Biosimilar Sales Quantity by Application (2024-2034) & (K Units)
Table 97. APAC Trastuzumab Biosimilar Revenue by Application (2018-2024) & (US$ Million)
Table 98. APAC Trastuzumab Biosimilar Revenue by Application (2024-2034) & (US$ Million)
Table 99. APAC Trastuzumab Biosimilar Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 100. APAC Trastuzumab Biosimilar Revenue by Region (2018-2024) & (US$ Million)
Table 101. APAC Trastuzumab Biosimilar Revenue by Region (2024-2034) & (US$ Million)
Table 102. APAC Trastuzumab Biosimilar Sales Quantity by Region (2018-2024) & (K Units)
Table 103. APAC Trastuzumab Biosimilar Sales Quantity by Region (2024-2034) & (K Units)
Table 104. Middle East, Africa and Latin America Trastuzumab Biosimilar Sales Quantity by Company (2018-2024) & (K Units)
Table 105. Middle East, Africa and Latin America Trastuzumab Biosimilar Revenue by Company (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Trastuzumab Biosimilar Sales Quantity by Type (2018-2024) & (K Units)
Table 107. Middle East, Africa and Latin America Trastuzumab Biosimilar Sales Quantity by Type (2024-2034) & (K Units)
Table 108. Middle East, Africa and Latin America Trastuzumab Biosimilar Revenue by Type (2018-2024) & (US$ Million)
Table 109. Middle East, Africa and Latin America Trastuzumab Biosimilar Revenue by Type (2024-2034) & (US$ Million)
Table 110. Middle East, Africa and Latin America Trastuzumab Biosimilar Sales Quantity by Application (2018-2024) & (K Units)
Table 111. Middle East, Africa and Latin America Trastuzumab Biosimilar Sales Quantity by Application (2024-2034) & (K Units)
Table 112. Middle East, Africa and Latin America Trastuzumab Biosimilar Revenue by Application (2018-2024) & (US$ Million)
Table 113. Middle East, Africa and Latin America Trastuzumab Biosimilar Revenue by Application (2024-2034) & (US$ Million)
Table 114. Middle East, Africa and Latin America Trastuzumab Biosimilar Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 115. Middle East, Africa and Latin America Trastuzumab Biosimilar Revenue by Country (2018-2024) & (US$ Million)
Table 116. Middle East, Africa and Latin America Trastuzumab Biosimilar Revenue by Country (2024-2034) & (US$ Million)
Table 117. Middle East, Africa and Latin America Trastuzumab Biosimilar Sales Quantity by Country (2018-2024) & (K Units)
Table 118. Middle East, Africa and Latin America Trastuzumab Biosimilar Sales Quantity by Country (2024-2034) & (K Units)
Table 119. Amgen Inc. Company Information
Table 120. Amgen Inc. Description and Overview
Table 121. Amgen Inc. Trastuzumab Biosimilar Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 122. Amgen Inc. Trastuzumab Biosimilar Product and Services
Table 123. Amgen Inc. Trastuzumab Biosimilar SWOT Analysis
Table 124. Amgen Inc. Recent Developments
Table 125. Pfizer Inc Company Information
Table 126. Pfizer Inc Description and Overview
Table 127. Pfizer Inc Trastuzumab Biosimilar Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 128. Pfizer Inc Trastuzumab Biosimilar Product and Services
Table 129. Pfizer Inc Trastuzumab Biosimilar SWOT Analysis
Table 130. Pfizer Inc Recent Developments
Table 131. Samsung Bioepis Company Information
Table 132. Samsung Bioepis Description and Overview
Table 133. Samsung Bioepis Trastuzumab Biosimilar Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 134. Samsung Bioepis Trastuzumab Biosimilar Product and Services
Table 135. Samsung Bioepis Trastuzumab Biosimilar SWOT Analysis
Table 136. Samsung Bioepis Recent Developments
Table 137. Merck & Co. Company Information
Table 138. Merck & Co. Description and Overview
Table 139. Merck & Co. Trastuzumab Biosimilar Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 140. Merck & Co. Trastuzumab Biosimilar Product and Services
Table 141. Merck & Co. Trastuzumab Biosimilar SWOT Analysis
Table 142. Merck & Co. Recent Developments
Table 143. Biocon Limited Company Information
Table 144. Biocon Limited Description and Overview
Table 145. Biocon Limited Trastuzumab Biosimilar Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 146. Biocon Limited Trastuzumab Biosimilar Product and Services
Table 147. Biocon Limited Trastuzumab Biosimilar SWOT Analysis
Table 148. Biocon Limited Recent Developments
Table 149. Teva Pharmaceutical Company Information
Table 150. Teva Pharmaceutical Description and Overview
Table 151. Teva Pharmaceutical Trastuzumab Biosimilar Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 152. Teva Pharmaceutical Trastuzumab Biosimilar Product and Services
Table 153. Teva Pharmaceutical Trastuzumab Biosimilar SWOT Analysis
Table 154. Teva Pharmaceutical Recent Developments
Table 155. Genentech Company Information
Table 156. Genentech Description and Overview
Table 157. Genentech Trastuzumab Biosimilar Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 158. Genentech Trastuzumab Biosimilar Product and Services
Table 159. Genentech Trastuzumab Biosimilar SWOT Analysis
Table 160. Genentech Recent Developments
Table 161. Mundipharma Company Information
Table 162. Mundipharma Description and Overview
Table 163. Mundipharma Trastuzumab Biosimilar Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 164. Mundipharma Trastuzumab Biosimilar Product and Services
Table 165. Mundipharma Trastuzumab Biosimilar SWOT Analysis
Table 166. Mundipharma Recent Developments
Table 167. Celltrion Company Information
Table 168. Celltrion Description and Overview
Table 169. Celltrion Trastuzumab Biosimilar Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 170. Celltrion Trastuzumab Biosimilar Product and Services
Table 171. Celltrion Trastuzumab Biosimilar SWOT Analysis
Table 172. Celltrion Recent Developments
Table 173. Henlius Company Information
Table 174. Henlius Description and Overview
Table 175. Henlius Trastuzumab Biosimilar Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 176. Henlius Trastuzumab Biosimilar Product and Services
Table 177. Henlius Trastuzumab Biosimilar SWOT Analysis
Table 178. Henlius Recent Developments
Table 179. Key Raw Materials Lists
Table 180. Raw Materials Key Suppliers Lists
Table 181. Trastuzumab Biosimilar Distributors List
Table 182. Trastuzumab Biosimilar Customers List
Table 183. Trastuzumab Biosimilar Market Trends
Table 184. Trastuzumab Biosimilar Market Drivers
Table 185. Trastuzumab Biosimilar Market Challenges
Table 186. Trastuzumab Biosimilar Market Restraints
Table 187. Research Programs/Design for This Report
Table 188. Key Data Information from Secondary Sources
Table 189. Key Data Information from Primary Sources
List of Figures
Figure 1. Trastuzumab Biosimilar Product Picture
Figure 2. Global Trastuzumab Biosimilar Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Trastuzumab Biosimilar Market Share by Type in 2022 & 2034
Figure 4. Adjuvant Breast Cancer Product Picture
Figure 5. Metastatic Breast Cancer Product Picture
Figure 6. Metastatic Gastric Cancer Product Picture
Figure 7. Others Product Picture
Figure 8. Global Trastuzumab Biosimilar Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 9. Global Trastuzumab Biosimilar Market Share by Application in 2022 & 2034
Figure 10. Hospital Pharmacy
Figure 11. Online Pharmacy
Figure 12. Trastuzumab Biosimilar Report Years Considered
Figure 13. Global Trastuzumab Biosimilar Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 14. Global Trastuzumab Biosimilar Revenue 2018-2034 (US$ Million)
Figure 15. Global Trastuzumab Biosimilar Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 16. Global Trastuzumab Biosimilar Sales Quantity 2018-2034 (K Units)
Figure 17. Global Trastuzumab Biosimilar Sales Quantity Market Share by Region (2018-2024)
Figure 18. Global Trastuzumab Biosimilar Sales Quantity Market Share by Region (2024-2034)
Figure 19. North America Trastuzumab Biosimilar Sales Quantity YoY (2018-2034) & (K Units)
Figure 20. North America Trastuzumab Biosimilar Revenue YoY (2018-2034) & (US$ Million)
Figure 21. Europe Trastuzumab Biosimilar Sales Quantity YoY (2018-2034) & (K Units)
Figure 22. Europe Trastuzumab Biosimilar Revenue YoY (2018-2034) & (US$ Million)
Figure 23. China Trastuzumab Biosimilar Sales Quantity YoY (2018-2034) & (K Units)
Figure 24. China Trastuzumab Biosimilar Revenue YoY (2018-2034) & (US$ Million)
Figure 25. APAC Trastuzumab Biosimilar Sales Quantity YoY (2018-2034) & (K Units)
Figure 26. APAC Trastuzumab Biosimilar Revenue YoY (2018-2034) & (US$ Million)
Figure 27. Middle East, Africa and Latin America Trastuzumab Biosimilar Sales Quantity YoY (2018-2034) & (K Units)
Figure 28. Middle East, Africa and Latin America Trastuzumab Biosimilar Revenue YoY (2018-2034) & (US$ Million)
Figure 29. The Top 10 and Top 5 Players Market Share by Trastuzumab Biosimilar Sales Quantity in 2022
Figure 30. The Top 10 and Top 5 Players Market Share by Trastuzumab Biosimilar Revenue in 2022
Figure 31. Trastuzumab Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Global Trastuzumab Biosimilar Sales Quantity Market Share by Type (2018-2034)
Figure 33. Global Trastuzumab Biosimilar Revenue Market Share by Type (2018-2034)
Figure 34. Global Trastuzumab Biosimilar Sales Quantity Market Share by Application (2018-2034)
Figure 35. Global Trastuzumab Biosimilar Revenue Market Share by Application (2018-2034)
Figure 36. North America Trastuzumab Biosimilar Revenue Market Share by Company in 2022
Figure 37. North America Trastuzumab Biosimilar Sales Quantity Market Share by Company in 2022
Figure 38. North America Trastuzumab Biosimilar Sales Quantity Market Share by Type (2018-2034)
Figure 39. North America Trastuzumab Biosimilar Revenue Market Share by Type (2018-2034)
Figure 40. North America Trastuzumab Biosimilar Sales Quantity Market Share by Application (2018-2034)
Figure 41. North America Trastuzumab Biosimilar Revenue Market Share by Application (2018-2034)
Figure 42. North America Trastuzumab Biosimilar Revenue Share by Country (2018-2034)
Figure 43. North America Trastuzumab Biosimilar Sales Quantity Share by Country (2018-2034)
Figure 44. United States Trastuzumab Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 45. Canada Trastuzumab Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 46. Europe Trastuzumab Biosimilar Sales Quantity Market Share by Company in 2022
Figure 47. Europe Trastuzumab Biosimilar Revenue Market Share by Company in 2022
Figure 48. Europe Trastuzumab Biosimilar Sales Quantity Market Share by Type (2018-2034)
Figure 49. Europe Trastuzumab Biosimilar Revenue Market Share by Type (2018-2034)
Figure 50. Europe Trastuzumab Biosimilar Sales Quantity Market Share by Application (2018-2034)
Figure 51. Europe Trastuzumab Biosimilar Revenue Market Share by Application (2018-2034)
Figure 52. Europe Trastuzumab Biosimilar Revenue Share by Country (2018-2034)
Figure 53. Europe Trastuzumab Biosimilar Sales Quantity Share by Country (2018-2034)
Figure 54. Germany Trastuzumab Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 55. France Trastuzumab Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 56. U.K. Trastuzumab Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 57. Italy Trastuzumab Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 58. Russia Trastuzumab Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 59. China Trastuzumab Biosimilar Sales Quantity Market Share by Company in 2022
Figure 60. China Trastuzumab Biosimilar Revenue Market Share by Company in 2022
Figure 61. China Trastuzumab Biosimilar Sales Quantity Market Share by Type (2018-2034)
Figure 62. China Trastuzumab Biosimilar Revenue Market Share by Type (2018-2034)
Figure 63. China Trastuzumab Biosimilar Sales Quantity Market Share by Application (2018-2034)
Figure 64. China Trastuzumab Biosimilar Revenue Market Share by Application (2018-2034)
Figure 65. APAC Trastuzumab Biosimilar Sales Quantity Market Share by Company in 2022
Figure 66. APAC Trastuzumab Biosimilar Revenue Market Share by Company in 2022
Figure 67. APAC Trastuzumab Biosimilar Sales Quantity Market Share by Type (2018-2034)
Figure 68. APAC Trastuzumab Biosimilar Revenue Market Share by Type (2018-2034)
Figure 69. APAC Trastuzumab Biosimilar Sales Quantity Market Share by Application (2018-2034)
Figure 70. APAC Trastuzumab Biosimilar Revenue Market Share by Application (2018-2034)
Figure 71. APAC Trastuzumab Biosimilar Revenue Share by Region (2018-2034)
Figure 72. APAC Trastuzumab Biosimilar Sales Quantity Share by Region (2018-2034)
Figure 73. Japan Trastuzumab Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 74. South Korea Trastuzumab Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 75. China Taiwan Trastuzumab Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 76. Southeast Asia Trastuzumab Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 77. India Trastuzumab Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 78. Middle East, Africa and Latin America Trastuzumab Biosimilar Sales Quantity Market Share by Company in 2022
Figure 79. Middle East, Africa and Latin America Trastuzumab Biosimilar Revenue Market Share by Company in 2022
Figure 80. Middle East, Africa and Latin America Trastuzumab Biosimilar Sales Quantity Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America Trastuzumab Biosimilar Revenue Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Trastuzumab Biosimilar Sales Quantity Market Share by Application (2018-2034)
Figure 83. Middle East, Africa and Latin America Trastuzumab Biosimilar Revenue Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Trastuzumab Biosimilar Sales Quantity Share by Country (2018-2034)
Figure 85. Middle East, Africa and Latin America Trastuzumab Biosimilar Revenue Share by Country (2018-2034)
Figure 86. Brazil Trastuzumab Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 87. Mexico Trastuzumab Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 88. Turkey Trastuzumab Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 89. Israel Trastuzumab Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 90. GCC Countries Trastuzumab Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 91. Trastuzumab Biosimilar Value Chain
Figure 92. Trastuzumab Biosimilar Production Process
Figure 93. Channels of Distribution (Direct Vs Distribution)
Figure 94. Distributors Profiles
Figure 95. Bottom-up and Top-down Approaches for This Report
Figure 96. Data Triangulation
Figure 97. Key Executives Interviewed